A Randomized, Open-label, Parallel Group Study in Patients With Bilateral Knee Osteoarthritis Comparing the Systemic Exposure of Triamcinolone Acetonide Following Administration Into Both Knees of Either Extended-release FX006 or Immediate-release TAcs (Triamcinolone Acetonide Suspension)

Trial Profile

A Randomized, Open-label, Parallel Group Study in Patients With Bilateral Knee Osteoarthritis Comparing the Systemic Exposure of Triamcinolone Acetonide Following Administration Into Both Knees of Either Extended-release FX006 or Immediate-release TAcs (Triamcinolone Acetonide Suspension)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Dec 2017

At a glance

  • Drugs Triamcinolone (Primary) ; Triamcinolone
  • Indications Osteoarthritis
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Flexion Therapeutics
  • Most Recent Events

    • 13 Dec 2017 New trial record
    • 07 Dec 2017 According to a Flexion Therapeutics media release, the first patient has been enrolled in this trial.
    • 07 Dec 2017 According to a Flexion Therapeutics media release, the company expects to report top-line results from this trial in the first half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top